At the news
? BULLISHIMPACT 6/10 6-K filed Sep 1, 2026 at 07:46 ET
GSK announced positive Phase II data for its mRNA seasonal flu vaccine candidate (FLUm3HA.b-3NA), showing higher immune responses vs. standard and high-dose vaccines in younger and older adults. The candidate targets both HA and NA antigens, a novel approach for mRNA flu vaccines. GSK will initiate a Phase III efficacy trial in September 2026, and the FDA granted Fast Track designation in July 2026. This is a positive pipeline catalyst but remains early-stage with no near-term revenue impact.
- Phase II data showed higher immune responses vs. standard and high-dose flu vaccines in younger and older adults.
- GSK intends to start a Phase III efficacy trial in September 2026.
- FDA granted Fast Track designation in July 2026.
- Vaccine candidate targets both haemagglutinin (HA) and neuraminidase (NA) antigens.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access